News / Events



is a non-steroidal anti-inflammatory drug (NSAID).  It is a cyclo-oxygenase (COX) enzyme inhibitor. It is reported to have a higher anti-inflammatory action or at least comparable effects than conventional NSAIDs in double-blind studies (Legrand 2004, Pareek and Chandurkar 2013, Pareek et al., 2011). It is effective in arthritic, dental and gynaecological pains among others (Dooley et al., 2001). In 1991, aceclofenac was developed as an analog of a commonly prescribed NSAID, Diclofenac, via chemical modification in effort to improve the gastrointestinal tolerability of the drug.
Aceclofenac displays more selectivity towards COX-2 (IC50 of 0.77 uM) than COX-1 (IC50 of >100 uM), which promotes its gastric tolerance compared to other NSAIDs (Legrand 2004). (The half maximal inhibitory concentration (IC50) is a measure of the effectiveness of a substance in inhibiting a specific biological or biochemical function).
Peak plasma concentrations are reached around 1.25 to 3 hours post-ingestion, and the drug penetrates into the synovial fluid where the concentration may reach up to 60% of that in the plasma

It may reduce the effects of some antihypertensives. It may increase the neuroexcitatory activity of quinolones among others.

Dooley M, Spencer CM, Dunn CJ: Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs. 2001;61(9):1351-78. (PubMed ID 11511027).
Legrand E: Aceclofenac in the management of inflammatory pain. Expert Opin Pharmacother. 2004 Jun:5(6):1347-57. (PubMed ID 15163279).  
Pareek A, Chandurkar N: Comparison of gastrointestinal safety and tolerability of aceclofenac with diclofenac: a multicenter, randomized, double-blind study in patients with knee osteoarthritis. Curr Med Res Opin. 2013 Jul;29(7):849-59.doi:10.1185/03007995.2013.795139.Epub 2013 Apr 30. (PubMed ID 23581533).

Published By
Pharm Ayobami 
Suppt Pharmacist at Aromokeye Pharm